Statute Details
- Title: Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013
- Act Code: MA1975-S38-2013
- Legislation Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act (Cap. 176), specifically powers under section 77
- Legislative Instrument No.: SL 38/2013
- Enacting Formula (maker): Minister for Health
- Deemed Commencement: 3 October 2011
- Key Provisions:
- Section 1: Citation and commencement (deemed operation on 3 Oct 2011)
- Section 2: Definition of “cosmetic product” by reference to the Health Products Act First Schedule
- Section 3: Cessation of application of the Medicines Act to cosmetic products from 3 Oct 2011
- Related Legislation: Health Products Act (Cap. 122D); Medicines Act (Cap. 176)
What Is This Legislation About?
The Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013 is a short but legally significant instrument. In essence, it provides that the Medicines Act stops applying to cosmetic products from a specified date. The Order is part of a regulatory transition: it aligns the legal treatment of cosmetic products with the framework under the Health Products Act.
In plain terms, the Order answers a practical regulatory question that matters to manufacturers, importers, distributors, and compliance teams: which law governs cosmetics—the Medicines Act or the Health Products Act. By directing that the Medicines Act ceases to apply to cosmetic products, the Order clarifies that cosmetics should be regulated under the Health Products regime (as defined by the Health Products Act’s First Schedule).
Although the Order is dated 2013, it is drafted with a deemed commencement of 3 October 2011. This means the legal effect is backdated to that earlier date. For practitioners, this backdating can be crucial when assessing compliance, enforcement actions, licensing, or historical conduct around the transition period.
What Are the Key Provisions?
Section 1 (Citation and commencement) establishes the formal name of the instrument and, importantly, its effective date. The Order “shall be deemed to have come into operation on 3rd October 2011.” This is not merely administrative: it determines when the cessation of the Medicines Act’s application took effect. Lawyers advising on matters involving events between 3 October 2011 and the date the Order was made (24 January 2013) must treat the cessation as having already occurred from the earlier date.
Section 2 (Definition) defines “cosmetic product” by reference to another statute. Specifically, it means a cosmetic product “referred to in the First Schedule to the Health Products Act (Cap. 122D).” This cross-reference is a drafting technique that ensures the definition stays consistent with the Health Products Act’s schedule. Practically, it means that the classification of a product as a “cosmetic product” is not determined solely by the Order itself; it depends on the Health Products Act’s First Schedule.
For legal practitioners, this cross-reference has two implications. First, product classification disputes may require analysis of the Health Products Act First Schedule and how it applies to the product’s intended use, composition, and claims. Second, any amendments to the First Schedule (if made in the future) could affect what falls within the definition of “cosmetic product” for purposes of the cessation Order—unless the Order is amended or interpreted otherwise.
Section 3 (Cessation of application of Act) is the operative provision. It states that “the provisions of the Act shall cease to apply to any cosmetic product as from 3rd October 2011.” The “Act” here refers to the Medicines Act (as indicated by the authorising powers and the title). The legal consequence is that, from that date, cosmetic products are no longer regulated under the Medicines Act’s provisions.
While the Order does not list which specific Medicines Act requirements stop applying (e.g., licensing, registration, or other regulatory controls), the cessation language is broad. It indicates that the Medicines Act’s entire set of provisions is withdrawn for cosmetic products. In practice, this typically shifts compliance obligations to the Health Products Act framework—meaning that the relevant approvals, notifications, standards, and enforcement mechanisms are those applicable to health products/cosmetics under the Health Products Act rather than medicines under the Medicines Act.
How Is This Legislation Structured?
The Order is structured in a simple three-part format:
(1) Section 1: Citation and commencement (including the deemed commencement date).
(2) Section 2: Definition of “cosmetic product” via reference to the Health Products Act First Schedule.
(3) Section 3: The cessation clause—ending the application of the Medicines Act to cosmetic products from 3 October 2011.
There are no schedules, no detailed regulatory procedures, and no transitional provisions within the text provided. The legal effect is achieved through the combination of (i) a backdated commencement and (ii) a categorical cessation clause.
Who Does This Legislation Apply To?
The Order applies to cosmetic products—not directly to persons. However, the regulated community is effectively anyone who deals with cosmetic products in Singapore: manufacturers, importers, distributors, retailers, and compliance professionals responsible for regulatory classification and product governance.
Because the definition of “cosmetic product” is tied to the Health Products Act First Schedule, the practical scope depends on whether a given product is within that schedule. Where a product is borderline (for example, where marketing claims or intended use could suggest a medicine rather than a cosmetic), the classification analysis becomes central. Lawyers advising on regulatory submissions or enforcement risk will therefore need to coordinate product classification under the Health Products Act with the consequences of the Medicines Act cessation under this Order.
Why Is This Legislation Important?
Although the Order is brief, it is important because it affects regulatory jurisdiction—which legal regime governs cosmetics. In Singapore’s regulatory landscape, the Medicines Act and the Health Products Act are distinct frameworks with different compliance expectations. By ceasing the Medicines Act’s application to cosmetic products, the Order reduces ambiguity and helps ensure that cosmetics are regulated under the appropriate statutory scheme.
From a compliance perspective, the Order has direct consequences for operational practice. Companies that previously treated cosmetics as falling under the Medicines Act may need to reassess their regulatory strategy: licensing/registration status, documentation, quality management expectations, and how product claims are handled. Even if the Order does not itself prescribe new obligations, it changes the legal “home” of those obligations.
From an enforcement and litigation perspective, the deemed commencement date is particularly significant. If an enforcement action, compliance audit, or dispute concerns conduct around or after 3 October 2011, parties must consider that the Medicines Act ceased to apply to cosmetic products from that date—even though the Order was made later. This can affect arguments about whether a particular regulatory requirement was legally applicable at the time of the conduct.
Finally, the cross-reference to the Health Products Act First Schedule means that classification is not static. Practitioners should monitor whether the Health Products Act schedule is amended, and how such amendments interact with the definition in this Order. While the cessation clause remains in force unless revoked or amended, the scope of what counts as a “cosmetic product” may evolve through changes to the First Schedule.
Related Legislation
- Medicines Act (Cap. 176)
- Health Products Act (Cap. 122D) (including the First Schedule referenced in the Order)
Source Documents
This article provides an overview of the Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.